BI-RADS, C-RADS, CAD-RADS, LI-RADS, Lung-RADS, NI-RADS, O-RADS,                     PI-RADS, TI-RADS: Reporting and Data Systems

An, Julie Y.; Unsdorfer, Kyle M. L.; Weinreb, Jeffrey C.

doi:10.1148/rg.2019190087

Cited by 80 publications

(37 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To conduct an objective detection, the thyroid imaging reporting and data system (TI-RADS) was proposed, which is used to classify thyroid nodules and recommend further treatment ( 6 ). Nowadays, there are five common classification systems used in clinic.…”

Section: Introductionmentioning

confidence: 99%

Comparison of Diagnostic Performance of Five Different Ultrasound TI-RADS Classification Guidelines for Thyroid Nodules

et al. 2020

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Comparison of Diagnostic Performance of Five Different Ultrasound TI-RADS Classification Guidelines for Thyroid Nodules

et al. 2020

View full text Add to dashboard Cite

“…Кроме того, используются различные протоколы МРТ для оценки ОЯ, а методы отчетности МРТ существенно варьируются между учреждениями [27,28]. Несоответствие на международном и национальном уровне и даже среди местных учреждений в использовании морфологических дескрипторов, а также характеристики изображений часто приводит к значительным различиям в последующей интерпретации [29].…”

Section: диагностика / Diagnosticsunclassified

О-RADS and ADNEX MR scoring system: standardization of assessment and modern approaches to stratification of ovarian malignancy risks

Solopova

Dudina

2020

Akušerstvo, ginekologiâ i reprodukciâ

View full text Add to dashboard Cite

This article reviews the studies published over the recent 10 years about diagnostic imaging of ovarian lesions (OL). We discuss the current classification systems considering the imaging criteria and the risks of malignancy as well as the ways of optimizing the treatment of patients. There are a number of methods of evaluation and interpretation of diagnostic data obtained using ultrasound as a first line method for OL visualization. To report the results, there is a unified terminology system O-RADS (Ovarian-Adnexal Reporting and Data System) developed specifically for ultrasound examinations. In 2013, the ADNEX MR (adnexal lesions magnetic resonance imaging) scoring system (AMRSS) was developed to standardize magnetic resonance data. That system combines the analysis of both basic-anatomical and functional MR-images and allows one to classify ovarian tumors by the risk of malignancy. Although O-RADS and AMRSS are based on different diagnostic modalities, they complement each other for the diagnostic purpose. In this review, we analyze correlations between the results obtained with these two methods; we also address the possibility of using the above methods in combination in order to pursue a more comprehensive approach to diagnosis of ovarian cancer.

show abstract

“…The chest X-ray or chest CT were done whenever possible for all patients. CT data were assessed by CORADS and Chest CT classification systems (Table 2) (12,13). Chest CT score: Each lung was assessed individually, and depending on the extent of involvement by consolidation or ground-glass opacity a score of 0 to 4 points was given (0 -no involvement, 1 -< 5% involvement, 2.…”

Section: Radiologic Analysismentioning

confidence: 99%

The effects of tocilizumab on clinical and laboratory features of patients with severe COVID-19: a single-center experience

Ashimov¹,

Kudaiberdiev²,

Abibillaev³

et al. 2020

HVT

View full text Add to dashboard Cite

Objective: Cytokine storm is considered as the immune hyperinflammatory process which may deteriorate the course of COVID-19. Interleukin (IL-6) inhibitors can be used in severe COVID-19 patients due to their anti-inflammatory and antiimmune effects. We aimed to assess the therapeutic effect of tocilizumab (Actemra) in patients with severe COVID-19 pneumonia. Methods: Overall, 1382 patients were admitted to a temporary hospital during July outbreak of COVID-19. Of these, 282 patients were hospitalized. Baseline clinical, radiological and laboratory data were collected from patient records. Laboratory markers prior to discharge were also collected. Wilcoxon rank sum test was conducted to show the significance of change of laboratory markers. Results: Eleven of the 282(3.9%) hospitalized patients who had severe pneumonia confirmed by either chest radiography (CXR) or computed tomography (CT) received tocilizumab (Actemra). Polymerase chain reaction (PCR) viral markers of COVID-19 were positive in three cases. Hypoxemia and surrogate markers of cytokine storm improved after the prescription of tocilizumab (p=0.003 in all laboratory parameters). Two of the patients who received tocilizumab have been transferred to reference centers. No mortality or adverse reactions case was registered. Conclusion: Our observational study demonstrated significant improvement in oxygen saturation, reduction in inflammatory markers-leukocytosis, CRP and D-dimers and 83% recovery without need for mechanical ventilation and no mortality in patients with COVID-19 with severe multilobar bilateral pneumonia and CT score 3-4 receiving tocilizumab in addition to standard treatment.

show abstract

BI-RADS, C-RADS, CAD-RADS, LI-RADS, Lung-RADS, NI-RADS, O-RADS, PI-RADS, TI-RADS: Reporting and Data Systems

Abstract: J.C.W.). Presented as an education exhibit at the 2018 RSNA Annual Meeting.

Cited by 80 publications

References 6 publications

Comparison of Diagnostic Performance of Five Different Ultrasound TI-RADS Classification Guidelines for Thyroid Nodules

Comparison of Diagnostic Performance of Five Different Ultrasound TI-RADS Classification Guidelines for Thyroid Nodules

О-RADS and ADNEX MR scoring system: standardization of assessment and modern approaches to stratification of ovarian malignancy risks

The effects of tocilizumab on clinical and laboratory features of patients with severe COVID-19: a single-center experience

Contact Info

Product

Resources

About